By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events